Imidazotiadiazol and imidazopirazina derived compounds as inhibitors of the protease activated receptor 2 (Par4)； Pharmaceutical composition that comprises； and its use to inhibit or prevent platelet aggregation and therefore useful in the treatment of thromboembolic disorder or pa The primary or secondary prophylaxis of thromboembolic disorders.
BRISTOL-MYERS SQUIBB COMPANY;UNIVERSITÉ DE MONTRÉAL
发明人:
BANVILLE, JACQUES,RÉMILLAR ROGER,RUEDIGER EDWARD H.,DEON DANIEL H.,GAGNON MARC,DUBÉ LAURENCE,GUY JULIA,PRIESTLEY ELDON SCOTT,POSY SHOSHANA L.,MAXWELL BRAD D.,WONG PANCRAS C.,LAWRENCE MICHAEL R.,MILLER
申请号：
CL2014002915
公开号：
CL2014002915A1
申请日:
2014.10.27
申请国别(地区):
CL
年份:
2015
代理人:
摘要：
The present invention provides thiazole compounds of Formula I wherein W, Y, R 0 , R 2 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 and X 4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.“COMPUESTOS DERIVADOS DE IMIDAZOTIADIAZOL E IMIDAZOPIRAZINA, INHIBIDORES DE PAR4； COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE； Y SU USO EN EL TRATAMIENTO DE UNA ENFERMEDAD TROMBOEMBOLICA”. PCT
